Jay Fishman, MD

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Independent contractor
    Ineligible company: 
    eGenesis
    Topic: 
    Xenotransplantation
    Date added: 
    11/23/2022
    Relationship end date: 
    11/30/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Independent contractor
    Ineligible company: 
    Sfunga
    Topic: 
    Antifungals
    Date added: 
    11/23/2022
    Relationship end date: 
    11/30/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Independent contractor
    Ineligible company: 
    Makana
    Topic: 
    Xenotransplantation
    Date added: 
    11/23/2022
    Relationship end date: 
    11/30/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Independent contractor
    Ineligible company: 
    Jura Inc.
    Topic: 
    CAR-T cells
    Date added: 
    11/23/2022
    Relationship end date: 
    11/30/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Independent contractor
    Ineligible company: 
    Abbott Pharma
    Topic: 
    ID Testing
    Date added: 
    11/23/2022
    Relationship end date: 
    11/30/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Independent contractor
    Ineligible company: 
    Well Medical
    Topic: 
    Education
    Date added: 
    11/23/2022
    Relationship end date: 
    11/30/2023
Return to 122 Infectious Diseases and Geographic Medicine Division Grand Rounds: "Infectious Risk and the Challenge of Safe Xenotransplantation" (120822)